7 takeover targets to look out for in 2017

After a slow 2016, industry followers expect at least a slight uptick in M&A next year as a new president, patent losses and promising markets entice further deals.

By Jacob Bell • Jan. 3, 2017

Report: Positive outlook for big pharma in 2017

At least one analyst believes there will be more catalysts in R&D and an uptick in M&A during the coming year. 

By Lisa LaMotta • Dec. 27, 2016

Prescribed Reading: An uptick in year-end M&A

Several companies are striking deals to round out the year, while others are trying to bury bad data, and the FDA cracks down on manufacturing. 

By Lisa LaMotta • Dec. 23, 2016

Novartis, Sun Pharma enter deal for oncology drug Odomzo

Approved in 2015, Odomzo hasn't been much of a revenue earner for Novartis but should help Sun expand its oncology offerings. 

By Jacob Bell • Dec. 23, 2016

Catalyst picks up manufacturing rights to hemophilia drug

The deal gives the U.S. biotech full cGMP manufacturing for clinical trials for the rare bleeding disorder. 

By Suzanne Elvidge • Dec. 22, 2016

Sygnis puts cash to use, acquires C.B.S. Scientific

The German company has expanded this year, also completing a takeover of proteomics device maker Expedeon back in September.

By Jacob Bell • Dec. 22, 2016

Japanese pharma snaps up cancer biotech Tolero

The acquisition expands Sumitomo Dainippon Pharma's pipeline in oncology and hematology. 

By Suzanne Elvidge • Dec. 22, 2016

Novartis buttresses Alcon with Encore Vision takeover

Helping to deliver on a promise made at the onset of 2016, Novartis plans to strengthen its Alcon business through an acquisition of Encore Vision.

By Jacob Bell • Dec. 21, 2016

Novartis sells US rights to 3 COPD drugs

Sunovion Pharmaceuticals will take over U.S. commercialization, although Novartis will continue to manufacture the medicines. 

By Jacob Bell • Dec. 21, 2016

Incyte puts up $200M in bispecifics deal with Merus

The collaboration will cover up to 11 bispecific antibody programs and could substantially expand Incyte's pipeline.

By Ned Pagliarulo • Dec. 21, 2016

Akebia partners with Otsuka on anemia drug

The Japanese co Otsuka will pay $125 million upfront, with another $140 million in committed funds tied to global development of vadadustat. 

By Suzanne Elvidge • Dec. 21, 2016

Allergan picks up regenerative med company for $2.9B

Since Allergan sold its generics business to Teva, CEO Brent Saunders has stayed true to his "stepping stone" dealmaking strategy. 

By Ned Pagliarulo • Dec. 20, 2016

Conatus soars on Novartis deal

The Swiss pharma put up $50 million to gain access to Conatus' experimental NASH drug, joining a growing list of biopharmas investing in the space.

By Ned Pagliarulo • Dec. 20, 2016

Bristol continues immuno-oncology push in deal with PsiOxus

The deal could be worth more than $930 million, and gives Bristol-Myers exclusive rights to a pre-clinical oncolytic virus therapy.

By Jacob Bell • Dec. 20, 2016

AstraZeneca uses Ionis to make sense from antisense

The $28 million milestone payment reflects progress in AstraZeneca's cancer pipeline.

By Suzanne Elvidge • Dec. 19, 2016

Prescribed Reading: Bad behavior abounds in biopharma

Charges have come down in a generics price-fixing investigation, while Ophthotech reports deep staff cutbacks and the FDA cautions on misleading advertising.

By Lisa LaMotta • Dec. 16, 2016

Celgene, Evotec team up on neurological treatments

The big biotech will pay the German drug discovery company $45 million upfront as part of the partnership.

By Jacob Bell • Dec. 16, 2016

Lonza swallows Capsugel in deal worth $5.5B

The deal caps off what has been a year of expansion for the Swiss drug manufacturer's pharmaceutical platform.

By Jacob Bell • Dec. 15, 2016

Grünenthal picks up rights to pain patch from Astellas

The German biopharma now holds the rights to market a capsaicin-based treatment for neurological pain in Europe, Africa and the Middle East.

By Jacob Bell • Dec. 13, 2016

Lilly, Express Scripts team up on insulin discount program

The pharma is playing nice with the PBM to help solidify its place in the competitive diabetes market. 

By Lisa LaMotta • Dec. 13, 2016

Almirall inks deal for Nuevolution's derm program

Spanish and Danish companies will collaborate on new class of NSAIDs.

By Suzanne Elvidge • Dec. 13, 2016

Purdue lands rights to psoriasis drug in diversification deal

Under scrutiny for its portfolio of pain drugs, Purdue is trying its hand in other areas of drug development. 

By Ned Pagliarulo • Dec. 12, 2016

Lilly and AZ hook up again for Alzheimer's

Lilly sticks with the amyloid approach in Alzheimer's even amid the recent high-profile failure of solanezumab.

By Suzanne Elvidge • Dec. 12, 2016

After rough 2016, markets to open for emerging biotech

It was a slow year for biotechs, with dealmaking and IPOs taking a back seat. But innovation and amazing science are at a peak, suggesting M&A will pick up. 

By Lisa LaMotta • Dec. 12, 2016

Endo chops sales force after ditching pain drug

The Irish biopharma plans to pump the resources saved from the decision into its branded drug portfolio.

By Jacob Bell • Dec. 8, 2016